What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view. #plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY

Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests? Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP

Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk

Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE I offer this to all pts w/SLE LN on MMF, but I do not push it #ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36

Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3

Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K

#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa

Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO

Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis https://t.co/pPLcsFLtG9

Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS

Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c